H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 28.36 CNY -5.5% Market Closed
Market Cap: 26B CNY
Have any thoughts about
Hubei Jumpcan Pharmaceutical Co Ltd?
Write Note

Hubei Jumpcan Pharmaceutical Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Jumpcan Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Interest Income Expense
ÂĄ422.6m
CAGR 3-Years
54%
CAGR 5-Years
59%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
ÂĄ1.1B
CAGR 3-Years
52%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
ÂĄ149.9m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
20%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
ÂĄ472.8m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
ÂĄ1.2B
CAGR 3-Years
-17%
CAGR 5-Years
-7%
CAGR 10-Years
37%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
-ÂĄ20.1m
CAGR 3-Years
-107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Jumpcan Pharmaceutical Co Ltd
Glance View

Market Cap
26.1B CNY
Industry
Pharmaceuticals

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs. The company is headquartered in Taizhou, Jiangsu and currently employs 6,632 full-time employees. The company went IPO on 2001-08-22. The firm's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The firm mainly distributes its products within domestic markets.

Intrinsic Value
46.9 CNY
Undervaluation 40%
Intrinsic Value
Price
H

See Also

What is Hubei Jumpcan Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
422.6m CNY

Based on the financial report for Jun 30, 2024, Hubei Jumpcan Pharmaceutical Co Ltd's Interest Income Expense amounts to 422.6m CNY.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
59%

Over the last year, the Interest Income Expense growth was 73%. The average annual Interest Income Expense growth rates for Hubei Jumpcan Pharmaceutical Co Ltd have been 54% over the past three years , 59% over the past five years .

Back to Top